1. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.003. Epub 2022
Dec  9.

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, 
SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, 
double-blind, placebo-controlled phase 1/2 clinical trial.

Hannawi S(1), Saf Eldin L(2), Abuquta A(1), Alamadi A(3), Mahmoud SA(4), Li 
J(5), Chen Y(5), Xie L(6).

Author information:
(1)Internal Medicine Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, 
United Arab Emirates.
(2)General Surgery Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, 
United Arab Emirates.
(3)Ear, Nose and Throat Department (ENT), Al Kuwait-Dubai (ALBaraha) Hospital, 
Dubai, United Arab Emirates.
(4)Biogenix labs, G42 Healthcare, Dubai, United Arab Emirates.
(5)Beijing Engineering Research Center of Protein and Antibody, Sinocelltech 
Ltd., Beijing, China.
(6)Beijing Engineering Research Center of Protein and Antibody, Sinocelltech 
Ltd., Beijing, China; Cell Culture Engineering Center, Chinese Academy of 
Medical Sciences & Peking Union Medical College, Beijing China. Electronic 
address: LX@sinocelltech.com.

Comment on
    J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018.

DOI: 10.1016/j.jinf.2022.12.003
PMCID: PMC9731927
PMID: 36509358 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Competing Interests Dr. Liangzhi 
Xie, Dr. Jian Li, and Dr. Yuanxin Chen are employees of Sinocelltech Ltd. and 
have ownership or potential stock option interests in the company. All authors 
declare no other conflicts of interest.